Skip to main content



NX Prenatal Inc. is a private US-based molecular diagnostics company with its corporate headquarters in Houston, TX and Lexington, KY. NX Prenatal is developing diagnostic assays for adverse pregnancy conditions such as preterm birth, preeclampsia, and placenta accreta. It employs a proprietary exosome-based liquid biopsy platform, which enables advanced isolation and enrichment of exosome and microvesicle particles from bodily fluids for non-invasive biomarker evaluation. Our tests are designed to provide physicians an ideal opportunity to intervene in a timely manner with protocols for at-risk pregnancies in an attempt to reduce complications that can arise from adverse pregnancy outcomes for both the child and the mother.

Our Vision

Our vision is to become a recognized leader in the advancement of women and children's health by providing innovative and novel methods to detect, monitor and manage pregnancy-related complications.

Management Team

Paul Kortschak

Chief Executive Officer

Paul is a diagnostic and life science tools industry veteran and brings over 20 years of experience to the NX Prenatal team, having served in senior executive roles at numerous leading public and private companies. Prior to joining NX Prenatal, Mr. Kortschak held executive level positions at Roche, Qiagen and Bio-Rad Laboratories, and he has extensive experience with biomarker discovery, clinical trials, and diagnostic assay development

Scott Gleason

Chief Financial Officer

Scott comes to NX Prenatal having previously served as the Interim CFO and as the SVP of Investor Relations and Corporate Communications at OraSure Technologies. Prior to OraSure he was the SVP of Investor Relations and Corporate Strategy at Myriad Genetics, a leading laboratory company. He also served as a financial analyst at Stephens Inc. covering the life science tools and diagnostics industry. He holds a degree in Economics from the United States Air Force Academy.

Kevin Rosenblatt, MD, PhD

Chief Medical & Scientific Officer

Dr. Rosenblatt previously served as CSO/CMO of CompanionDx Labs, a precision medicine company focused on diagnostics. With 26 years of experience as a renowned molecular pathologist and industry veteran, Dr. Rosenblatt is recognized internationally for proteomics and genomics with an emphasis on oncology, drug metabolism, and neurode generative diseases. He also previously served as CEO of Risk Assessment Laboratories, which focused on preterm birth biomarkers in conjunction with Perkin-Elmer.

Board of Directors and Advisors

C. David Adair, MD, MBA

Board Chair

Dr. Adair is the Co-Founder and Managing Director of Solas Bioventures. Board-certified in Maternal-Fetal Medicine, Obstetrics and Gynecology, and Hypertension, with special expertise in Critical Care, Dr. Adair is a long-time physician, educator, administrator, innovator, and biotech/med-tech investor with nearly 20 years of experience in angel and venture investing. He recently retired from his position as Professor and Vice Chairman of the Department of Obstetrics and Gynecology at the University of Tennessee College of Medicine, and also retired from clinical practice after a 30-year career.

Alan Mack


Mr. Mack is a successful entrepreneur and executive in the diagnostics field, and is the Founder, President and CEO of NxGEN MDx LLC, a leading clinical molecular diagnostics laboratory providing best-in-class genetic carrier screening tests as trusted tools for early family planning. He previously held executive leadership positions at Arctic Medical Laboratories, Asendant MDx, and the Sequenom Center for Molecular Medicine. Earlier in his career, Mr. Mack held diagnostics sales leadership positions at firms including TM Bioscience and Quest Diagnostics.

Mary Lake Polan, MD, PhD, MPH


Dr. Polan is a Clinical Professor in the Department of Obstetrics and Gynecology and Reproductive Sciences at Yale University School of Medicine; she is also Chair Emeritus of the Department of Obstetrics and Gynecology at Stanford University. She has published more than 130 articles, chapters, and books in her areas of research, which include reproductive endocrinology and infertility. She is a member of the National Academy of Medicine and has served on a number of NIH and university committees.

Robert S. Saunders


Mr. Saunders is a General Partner of OCA Ventures (Chicago), a Founding Partner of Saunders Murdock and Associates (Louisville/Boston), and is an active investor in many healthcare startups. Mr. Saunders was a Managing Director and General Partner at Chrysalis Ventures from 1997 to 2009. Over the last 30 years, he has invested in several dozen startup companies and has mentored 100+ startups. He received a B.A. from Stanford University, an M.Sc. from the London School of Economics, and an M.A. from Harvard University. He was both a Fulbright Scholar and a Marshall Scholar.

Alan Ezrin Ph.D.


Dr. Ezrin has served as a Director and C-level officer of ten public and privately held life science companies. He was the co-founder of Cardiome Pharma and ConjuChem, both of which matured from start-up stage to multi-hundred million dollar market cap firms under his scientific and business leadership. Dr. Ezrin has 35+ years of experience in research and business development in both the pharmaceutical/biotechnology sectors in the US & Canada. He holds a Ph.D. in pharmacology from the University of Miami, and serves on the Board of NX PharmaGen and on the Board of Advisors for the Preston Robert Tisch Brain Tumor Center at Duke University.

Zhen Zhang, Ph.D.

Advisory Board Member

Dr. Zhang is an expert in bioinformatics and statistics and is the associate director of the Center for Biomarker Discovery and Translation at John Hopkins University School of Medicine. Dr. Zhang has conducted biomarker research for over 20 years, particularly in the design of biomarker discovery and validation studies and the development of in vitro diagnostic multivariate index assays (IVDMIA) for clinical applications. He was an integral part of the discovery and development of the OVA1 test for pre-surgery assessment of malignancy risk for women diagnosed with pelvic mass. OVA1 was the first ever IVDMIA protein marker test cleared by FDA for clinical use.

Danielle Scelfo, MHSA

Advisory Board Member

Ms. Scelfo is the VP of Market Access and Health Policy at ClearNote Health, and formerly served in similar executive leadership roles at CareDx and Hologic Incorporated. An experienced industry veteran, Ms. Scelfo has chaired the Reimbursement and Policy Workgroup for the Coalition for 21st Century Medicine, co-chaired the Diagnostics Workgroup for the California Healthcare Institute and has been an active member of the two leading US diagnostic trade associations, AdvaMed Dx and the American Clinical Lab Association. Ms. Scelfo has a comprehensive understanding of the US diagnostic industry, Medicare and Medicaid programs, and managed care delivery systems. Her extensive knowledge of government and commercial payer reimbursement lends valuable insights to the financial impact of reimbursement policy, legislation, and the regulatory rule-making process in healthcare.

Robert G. Bonebrake, MD, FACOG

Advisory Board Member

Dr. Bonebrake is a partner with Perinatal Associates at The Methodist Perinatal Center at Nebraska Methodist Women’s Hospital. He is also a Clinical Associate Professor in the Department of Obstetrics and Gynecology at the University of Nebraska Medical Center and currently serves as the President of the Medical Staff for Nebraska Methodist Health System, and is the past Chair of the Department of Maternal and Child for Methodist Health System. Dr. Bonebrake also serves as the Chair of the State of Nebraska Maternal Mortality Committee and the Co- Medical Director of the Nebraska Perinatal Quality Improvement Collaborative. He has numerous publications and has many invited presentations, with special emphasis on antenatal diagnosis of complications of pregnancy and delivery.

Daniel W. Chan, PhD, DABCC, FACB

Advisory Board Member

Dr. Chan is a Professor of Pathology, Oncology, Radiology, and Urology at the Johns Hopkins University School of Medicine and Director of the Clinical Chemistry Division and Co-Director of the Pathology Core Laboratory of Johns Hopkins Hospital in Baltimore. Dr. Chan is also the Director of the Biomarker Discovery and Translation Center at Johns Hopkins University. Dr. Chan received his BA degree in Biology from the University of Oregon and his Ph.D. in Biochemistry from the State University of New York at Buffalo. He is an internationally recognized expert in cancer biomarkers, clinical proteomics, and molecular diagnostics. He has written 5 books, 40 book chapters, and 300 scientific articles. He is the Editor-in-Chief of the journal Clinical Proteomics.

Thomas McElrath, MD, PhD, FACOG

Advisory Board Member

Dr. McElrath is an Associate Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School and an attending physician at Brigham & Women's Hospital, where he specializes in Maternal & Fetal Medicine with a focus on the prevention of spontaneous preterm birth. Dr. McElrath manages the Preterm Birth Clinic at Brigham and Women’s Hospital. He actively publishes on the biomarker epidemiology and classification of preterm birth and the interaction of environmental conditions and exposures with the risk of preterm birth.

Robert C. Doss Ph.D.

VP Product Development

Dr. Doss is a Senior Executive with more than 25 years of Leadership experience in the Global Diagnostics and related Health Care fields. He has an exemplary record in delivering over 80 new products to market within a $3B business unit of Abbott Diagnostics. He held senior management positions in domestic and international R&D, Quality Assurance, Regulatory Affairs and Technical Product Support. Dr. Doss has proven experience in organizational assessment, organizational design, talent management and talent acquisition, and has earned a reputation as results-oriented, practical, analytical, innovative and collaborative.

Gail Page

Strategic Advisor

Gail Page serves as Managing Partner of pH Blueprint, leveraging 35+ years of executive experience and networks to benefit clients in the diagnostic and clinical laboratory spaces. Gail is an accomplished public CEO, leading Vermillion and Chembio through industry-defining pivots and product launches. She is a seasoned executive leader with notable tenures at LabCorp, Luminex, and Vermillion. Gail has been instrumental in raising over $175M in public and private funding. Her current board appointments include Sword Bio, Inc, Mellitus, LLC, and MARAbio. In addition to the above, she serves as a Venture Partner for Turret Capital.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Partners and Collaborators

World-class leaders in the fields of biomedical research, proteomics, and clinical molecular diagnostics have partnered with NX Prenatal to develop its groundbreaking technology.